Eli Lilly Surges on FDA Nod for Zepbound
Eli Lilly shares rise as FDA approves Zepbound for weight-loss, aiding sleep apnea. Discover the impact on LLY stock and market trends.
Eli Lilly shares climbed following FDA approval of its weight-loss treatment Zepbound.